Entry Comp. X R1 R2 EC50b (μM) CC50c (μM) TId
1 5a CH2 Ph OEt 63.37 234.02 3.69
2 5b CH2 2-FPh OEt 252.56 >581.40 >2.30
3 5c CH2 4-FPh OEt 88.89 323.32 3.64
4 5d CH2 2-OMePh OEt 57.58 395.39 6.87
5 5e CH2 3-OMePh OEt 213.17 >561.80 >2.64
6 5f CH2 4-OMePh OEt 69.18 243.69 3.52
7 5g CH2 3,4-OMePh OEt 288.91 >518.13 >1.79
8 5h CH2 naphthalen-1-yl OEt 48.32 >531.91 >11.01
9 5i CH(CH3) Ph OEt 68.79 320.09 4.65
10 6a NH 4-FPh OEt 32.61 213.01 6.53
11 6b NH 4-ClPh OEt 14.59 135.46 9.28
12 7a CH2CH2 Ph OEt 55.91 376.18 6.73
13 7b CH2CH2 2-FPh OEt 44.83 148.80 3.32
14 7c CH2CH2 3-FPh OEt 52.26 176.42 3.38
15 7d CH2CH2 4-FPh OEt 1.65 13.16 7.98
16 7e CH2CH2 4-ClPh OEt 15.16 145.43 9.59
17 7f CH2CH2 4-MePh OEt 2.34 15.45 6.60
18 7g CH2CH2 4-SO2NH2 OEt 136.42 173.46 1.27
19 7h CH2CH2 4-OMePh OEt 163.92 232.97 1.42
20 7i CH2CH2 3,4-OMePh OEt 9.15 33.52 3.66
21 7j CH2CH2 indol-3-yl OEt 9.37 26.73 2.85
22 8a CH2CH2 4-MePh NH(4-FBn) 40.37 164.60 4.08
23 8b CH2CH2 4-MePh NH(2-OMeBn) 32.70 215.82 6.60
24 8c CH2CH2 4-MePh NHCH2CH(CH2CH2) 36.41 306.17 8.41
25 8d CH2CH2 4-FPh NH(4-FBn) 5.70 30.76 5.40
26 8e CH2CH2 4-FPh NH(2-OMeBn) 63.01 224.25 3.56
27 8f CH2CH2 3,4-OMePh NH(2-OMeBn) 149.25 217.70 1.46
28 9a CH2CO 4-BrPh OEt 54.27 >464.04 >8.55
29 9b CH2CH(CH3) Ph OEt 25.14 146.10 5.81
30 9c CH2CH(Ph) Ph OEt 3.10 25.22 8.14
31 9d CH(COOMe)CH2 Ph OEt 185.55 346.88 1.87
32 10 CH2CH2CH2 Ph OEt 59.15 206.41 3.49
33 11 1,2,3,4-tetrahydronaphthalen-1-yl OEt 36.64 132.92 3.63
34 12 propyl OEt 352.81 >719.42 >2.03
35 13 t-butyl OEt 119.38 >684.93 >5.74
36 AZTe - - - 0.0085 3779 444588
aValues are means of two separate experiments.
bCC50 (50% cytotoxic concentration), concentration of drug that causes 50%reduction in total C8166 cell number.
c
EC50 (50% effective concentration), concentration of drug that reduces syncytiaformation by 50%.
d In vitro therapeutic index (CC50 value/EC50 value). eAZT was used as a positive control.
Table 1: Anti-HIV activity of compounds 5-13 in vitroa.